title: Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma.
abstract: This report summarizes 2 years experience in performing 336 autotransplant procedures in 251 consecutive patients with multiple myeloma, using high-dose melphalan at 200 mg/m2 in the context of a tandem transplant program. A total of 91 patients received 118 transplants as outpatients while the remaining 160 patients received 218 transplants as inpatients. Outpatients were more often younger, with better stem cell products, normal serum albumin and beta-2-microglobulin levels as well as chemotherapy-sensitive disease compared to inpatients. There were no differences in hematopoietic recovery and non-hematologic toxicities between outpatient and inpatient transplant recipients. Post-transplant febrile neutropenia and most other post-transplant toxicities were managed successfully in an ambulatory setting. Although liberal criteria were developed for hospitalization of outpatients, including clinical parameters as well as patient desire and physician/nurse judgement, only 21% of outpatients required admission after transplantation. Median hospital stay for these outpatients was 9 days, while inpatients were hospitalized for a median of 15 days (P = 0.0001). After adjusting for differences in disease and host features, our study showed outpatient management resulted in significant financial savings due to lower pharmacy (42%), hospitalization (50%) and pathology/laboratory charges (36%). We conclude that outpatient transplants should facilitate access to myeloablative therapy, thereby improving complete remission rates and survival of myeloma patients.
authors.affiliation: Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock 72205, USA.
authors.forename: S
authors.initials: S
authors.lastname: Jagannath
authors.forename: D H
authors.initials: DH
authors.lastname: Vesole
authors.forename: M
authors.initials: M
authors.lastname: Zhang
authors.forename: K R
authors.initials: KR
authors.lastname: Desikan
authors.forename: N
authors.initials: N
authors.lastname: Copeland
authors.forename: M
authors.initials: M
authors.lastname: Jagannath
authors.forename: D
authors.initials: D
authors.lastname: Bracy
authors.forename: R
authors.initials: R
authors.lastname: Jones
authors.forename: J
authors.initials: J
authors.lastname: Crowley
authors.forename: G
authors.initials: G
authors.lastname: Tricot
authors.forename: B
authors.initials: B
authors.lastname: Barlogie
mesh_terms: D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000191:economics*; D016026:Bone Marrow Transplantation / Q000191:economics*; D003362:Cost-Benefit Analysis; D005240:Feasibility Studies; D005251:Fees, Medical; D005252:Fees, Pharmaceutical; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics; D017722:Hospital Charges; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000191:economics* / Q000628:therapy*; D010343:Patient Admission / Q000191:economics; D014182:Transplantation, Autologous
chemical_list: D008558:Melphalan